Business
AXIM Biotech Soars After Analyst Issues $17 Price Target -- SECFilings.com
AXIM Biotech Soars After Analyst Issues $17 Price Target -- SECFilings.com.
About this update from Axim Biotechnologies, Inc.
[{"type":"text","content":"\n \n \n AXIM Biotech Soars After Analyst Issues $17 Price Target -- SECFilings.com\n \n \nAXIM Biotech Soars After Analyst Issues $17 Price Target -- SECFilings.com\n \n REDONDO BEACH, CA--(Marketwired - May 18, 2017) -  SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces the publication of an article covering AXIM® Biotechnologies Inc. (OTCQB: AXIM). SeeThruEquity recently initiated the stock with a $17 per share price target -- a 62% premium to the current market price of $10.52 per share, as of May 17, 2017. The article takes a closer look at the SeeThruEquity research report and the implications for AXIM moving forward.\n AXIM Biotech operates in the legal nutraceutical and pharmaceutical subset of the cannabis industry, but SeeThruEquity notes the rapidly advancing legalization movement is likely to have an impact on its valuation and market perception. This may be especially true with the upcoming launch of several new exchange-traded funds (ETFs) that aim to target the cannabis industry since they will likely hold an oversized position in AXIM Biotech given its market capitalization.\n Several Catalysts for 2017\n AXIM Biotech has several upcoming catalysts that could favorably impact its valuation over the coming quarters. The company launched its CanChew®, a patented, controlled-release cannabis chewing gum for general wellbeing, in all 50 states and 40 countries. With more than 10 commercial-ready products in nutraceutical, cosmeceutical, and oral care markets, the company is already generating revenue without the need for regulatory approvals.\n In addition to these products, the company has more than 20 clinical products planned and is in the process of developing pharmaceutical candidates using chewing gum and other delivery methods -- including suppositories, transdermals, and transconjuctivals. These products are expected to begin reporting trial results this year.\n SeeThruEquity pointed out that lesser-known products in the pipeline could become new category leaders. For instance, the company's Oraximax™ is a cannabinoid product that management hopes will define a new category of oral care products thanks to its anti-inflammatory, anti-proliferative, and bactericidal properties. The company also offers lozenge ...